NUP210 and primary biliary cholangitis: Anti-gp210, unlike AMA, in patients with PBC has been associated with disease severity and poor prognosis in some studies (Muratori et al., 2003; Invernizzi et al., 2005), but not others (Stinton et al., 2011).